Why Profitability Doesn’t Matter: Seattle Genetics

Bothell-based biotech company Seattle Genetics recently announced it’s largest funding initiative. Increasing their public stock offering from $480 million to $552 million, the company made this move after noticing a peak in interest from investors. CEO Clay Siegall said that the money will be primarily used to expand their workforce, projecting the addition of 100 […]... Read More